Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.
Diabetes is an independent predictor of morbidity and mortality in patients with symptomatic heart failure, patients with asymptomatic left ventricular dysfunction (defined as an ejection fraction of 35% or less), and in a broader registry population with less stringent entry criteria. Although the SOLVD Trials made a major clinical contribution by proving the value of enalapril, diabetes remains a significant predictor of outcome even after adjusting for treatment with enalapril.
Shindler
D M
DM
University of Medicine and Dentistry-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA.
Kostis
J B
JB
Yusuf
S
S
Quinones
M A
MA
Pitt
B
B
Stewart
D
D
Pinkett
T
T
Ghali
J K
JK
Wilson
A C
AC
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000401:mortality; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D016017:Odds Ratio; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012044:Regression Analysis; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000150:complications* / Q000188:drug therapy / Q000401:mortality
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril